BACKGROUND: Idiopathic inflammatory myopathies (IIM) are associated with systemic inflammation, limited mobility, and glucocorticoid therapy, all of which can lead to metabolism disturbances, atherogenesis, and increased cardiovascular (CV) risk. The aim of this study was to assess the CV risk in IIM patients and healthy controls (HC), and its association with disease-specific features. METHODS: Thirty nine patients with IIM (32 females; mean age 56; mean disease duration 4.8 years; dermatomyositis: n = 16, polymyositis: n = 7, immune-mediated necrotizing myopathy: n = 8, anti-synthetase syndrome: n = 8) and 39 age-/sex-matched HC (32 females, mean age 56) without rheumatic diseases were included. In both groups, subjects with a history of CV disease (angina pectoris, myocardial infarction, cerebrovascular, and peripheral arterial vascular events) were excluded. Muscle involvement, disease activity, and tissue damage were evaluated (Manual Muscle Test-8, Myositis Intention to Treat Activity Index, Myositis Damage Index). Comorbidities and current treatment were recorded. All participants underwent examinations of carotid intima-media thickness (CIMT), pulse wave velocity (PWV), ankle-brachial index (ABI), and body composition (by densitometry and bioelectric impedance). The risk of fatal CV events was evaluated by the Systematic COronary Risk Evaluation (SCORE, charts for the European population) and its modifications. RESULTS: Compared to HC, there was no significant difference in IIM patients regarding blood pressure, ABI, PWV, CIMT, and the risk of fatal CV events by SCORE or SCORE2, or subclinical atherosclerosis (CIMT, carotid plaques, ABI, and PWV). The calculated CV risk scores by SCORE, SCORE2, and SCORE multiplied by the coefficient 1.5 (mSCORE) were reclassified according to the results of carotid plaque presence and CIMT; however, none of them was demonstrated to be significantly more accurate. Other significant predictors of CV risk in IIM patients included age, disease duration and activity, systemic inflammation, lipid profile, lean body mass, and blood pressure. CONCLUSIONS: No significant differences in CV risk factors between our IIM patients and HC were observed. However, in IIM, CV risk was associated with age, disease duration, duration of glucocorticoid therapy, lipid profile, and body composition. None of the currently available scoring tools (SCORE, SCORE2, mSCORE) used in this study seems more accurate in estimating CV risk in IIM.

3rd Department of Internal Medicine General University Hospital and 1st Faculty of Medicine Charles University Prague Czechia

Department of Human Movement Laboratory Faculty of Physical Education and Sport Charles University Prague Czechia

Department of Physiotherapy Faculty of Physical Education and Sport Charles University Prague Czechia

Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czechia

Faculty of Mathematics and Physics Charles University Prague Czechia

Institute of Rheumatology Prague Czechia

See more in PubMed

Lundberg IE, de Visser M, Werth VP. Classification of myositis. Nat Rev Rheumatol. (2018) 14:269–78. 10.1038/nrrheum.2018.41 PubMed DOI

Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. (1975) 292:344–7. 10.1056/NEJM197502132920706 PubMed DOI

Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. (1975) 292:403–7. 10.1056/NEJM197502202920807 PubMed DOI

Rose MR, Group EIW. 188th ENMC International Workshop: Inclusion Body Myositis, 2-4 December 2011, Naarden, The Netherlands. Neuromusc Disord. (2013) 23:1044–55. 10.1016/j.nmd.2013.08.007 PubMed DOI

Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. . 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromusc Disord. (2004) 14:337–45. 10.1016/j.nmd.2004.02.006 PubMed DOI

Miller FW, Lamb JA, Schmidt J, Nagaraju K. Risk factors and disease mechanisms in myositis. Nat Rev Rheumatol. (2018) 14:255–68. 10.1038/nrrheum.2018.48 PubMed DOI PMC

Sanjadi M, Rezvanie Sichanie Z, Totonchi H, Karami J, Rezaei R, Aslani S. Atherosclerosis and autoimmunity: a growing relationship. Int J Rheum Dis. (2018) 21:908–21. 10.1111/1756-185X.13309 PubMed DOI

Castaneda S, Martin-Martinez MA, Gonzalez-Juanatey C, Llorca J, Garcia-Yebenes MJ, Perez-Vicente S, et al. . Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: baseline data of the CARMA Project. Semin Arthritis Rheum. (2015) 44:618–26. 10.1016/j.semarthrit.2014.12.002 PubMed DOI

Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. . ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. (2011) 217:3–46. 10.1016/j.atherosclerosis.2011.06.028 PubMed DOI

Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. (1991) 121:293–8. 10.1016/0002-8703(91)90861-B PubMed DOI

Kerekes G, Soltesz P, Nurmohamed MT, Gonzalez-Gay MA, Turiel M, Vegh E, et al. . Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nat Rev Rheumatol. (2012) 8:224–34. 10.1038/nrrheum.2012.16 PubMed DOI

Ungprasert P, Suksaranjit P, Spanuchart I, Leeaphorn N, Permpalung N. Risk of coronary artery disease in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis of observational studies. Semin Arthritis Rheum. (2014) 44:63–7. 10.1016/j.semarthrit.2014.03.004 PubMed DOI

Dobloug GC, Svensson J, Lundberg IE, Holmqvist M. Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study. Ann Rheum Dis. (2018) 77:40–7. 10.1136/annrheumdis-2017-211402 PubMed DOI

Rai SK, Choi HK, Sayre EC, Avina-Zubieta JA. Risk of myocardial infarction and ischaemic stroke in adults with polymyositis and dermatomyositis: a general population-based study. Rheumatology. (2016) 55:461–9. 10.1093/rheumatology/kev336 PubMed DOI

Schwartz T, Diederichsen LP, Lundberg IE, Sjaastad I, Sanner H. Cardiac involvement in adult and juvenile idiopathic inflammatory myopathies. RMD Open. (2016) 2:e000291. 10.1136/rmdopen-2016-000291 PubMed DOI PMC

Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. . Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. (2003) 24:987–1003. 10.1016/S0195-668X(03)00114-3 PubMed DOI

SCORE2 working group and ESC Cardiovascular risk collaboration . SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. (2021) 42:2439–54. 10.1093/eurheartj/ehab309 PubMed DOI PMC

Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, et al. . EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. (2017) 76:17–28. 10.1136/annrheumdis-2016-209775 PubMed DOI

Nambi V, Chambless L, Folsom AR, He M, Hu Y, Mosley T, et al. . Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol. (2010) 55:1600–7. 10.1016/j.jacc.2009.11.075 PubMed DOI PMC

Ankle Brachial Index C, Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, et al. . Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. (2008) 300:197–208. 10.1001/jama.300.2.197 PubMed DOI PMC

Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. . Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. (2006) 27:2588–605. 10.1093/eurheartj/ehl254 PubMed DOI

Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. . 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. (2017) 69:2271–82. 10.1002/art.40320 PubMed DOI PMC

Miller FW. New approaches to the assessment and treatment of the idiopathic inflammatory myopathies. Ann Rheum Dis. (2012) 71(Suppl. 2):i82–5. 10.1136/annrheumdis-2011-200587 PubMed DOI

Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, et al. . International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology. (2004) 43:49–54. 10.1093/rheumatology/keg427 PubMed DOI

Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, et al. . Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res. (2011) 63(Suppl. 11):S118–57. 10.1002/acr.20532 PubMed DOI PMC

Bukhari M, Kent A. How rheumatologists assess disability in the current era needs an overhaul: focus on the Health Assessment Questionnaire. Rheumatology. (2020) 59:267–8. 10.1093/rheumatology/kez423 PubMed DOI

Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. (1992) 30:473–83. 10.1097/00005650-199206000-00002 PubMed DOI

Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis. (1994) 18(Suppl. 1):S79–83. 10.1093/clinids/18.Supplement_1.S79 PubMed DOI

Belza B, Miyawaki CE, Liu M, Aree-Ue S, Fessel M, Minott KR, et al. . A systematic review of studies using the multidimensional assessment of fatigue scale. J Nurs Meas. (2018) 26:36–75. 10.1891/1061-3749.26.1.36 PubMed DOI

Davidson M, de Morton N. A systematic review of the Human Activity Profile. Clin Rehabil. (2007) 21:151–62. 10.1177/0269215506069475 PubMed DOI

Hubley AM. Beck depression inventory. In: Michalos AC, editor. Encyclopedia of Quality of Life and Well-Being Research. Dordrecht: Springer Netherlands; (2014). p. 338–45.

Hermankova B, Spiritovic M, Oreska S, Storkanova H, Komarc M, Klein M, et al. . Sexual function in patients with idiopathic inflammatory myopathies: a cross-sectional study. Rheumatology. (2021) 60:5060–72. 10.1093/rheumatology/keab397 PubMed DOI PMC

Spiritovic M, Hermankova B, Oreska S, Storkanova H, Ruzickova O, Vernerova L, et al. . The effect of a 24-week training focused on activities of daily living, muscle strengthening, and stability in idiopathic inflammatory myopathies: a monocentric controlled study with follow-up. Arthritis Res Ther. (2021) 23:173. 10.1186/s13075-021-02544-5 PubMed DOI PMC

Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem. (2001) 34:583–8. 10.1016/S0009-9120(01)00263-6 PubMed DOI

Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Manuel Gomez J, et al. . Bioelectrical impedance analysis-part II: utilization in clinical practice. Clin Nutr. (2004) 23:1430–53. 10.1016/j.clnu.2004.09.012 PubMed DOI

Majtan B, Zelinka T, Rosa J, Petrak O, Kratka Z, Strauch B, et al. . Long-term effect of adrenalectomy on cardiovascular remodeling in patients with pheochromocytoma. J Clin Endocrinol Metab. (2017) 102:1208–17. 10.1210/jc.2016-2422 PubMed DOI

Howard G, Sharrett AR, Heiss G, Evans GW, Chambless LE, Riley WA, et al. . Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC Investigators. Stroke. (1993) 24:1297–304. 10.1161/01.STR.24.9.1297 PubMed DOI

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. . 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. (2018) 36:1953–2041. 10.1097/HJH.0000000000001940 PubMed DOI

Johri AM, Nambi V, Naqvi TZ, Feinstein SB, Kim ESH, Park MM, et al. . Recommendations for the assessment of carotid arterial plaque by ultrasound for the characterization of atherosclerosis and evaluation of cardiovascular risk: from the American Society of Echocardiography. J Am Soc Echocardiogr. (2020) 33:917–33. 10.1016/j.echo.2020.04.021 PubMed DOI

Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK, et al. . 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. (2011) 58:2020–45. 10.1161/CIR.0b013e31822e80c3 PubMed DOI PMC

Bruno RM, Bianchini E, Faita F, Taddei S, Ghiadoni L. Intima media thickness, pulse wave velocity, and flow mediated dilation. Cardiovasc Ultrasound. (2014) 12:34. 10.1186/1476-7120-12-34 PubMed DOI PMC

Petrak O, Rosa J, Holaj R, Strauch B, Kratka Z, Kvasnicka J, et al. . Blood pressure profile, catecholamine phenotype, and target organ damage in pheochromocytoma/paraganglioma. J Clin Endocrinol Metab. (2019) 104:5170–80. 10.1097/01.hjh.0000570340.25772.0c PubMed DOI

Reference Values for Arterial Stiffness C. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J. (2010) 31:2338–50. 10.1093/eurheartj/ehq165 PubMed DOI PMC

Rundek T, Arif H, Boden-Albala B, Elkind MS, Paik MC, Sacco RL. Carotid plaque, a subclinical precursor of vascular events: the Northern Manhattan Study. Neurology. (2008) 70:1200–7. 10.1212/01.wnl.0000303969.63165.34 PubMed DOI PMC

Laporte A, Mariampillai K, Allenbach Y, Pasi N, Donciu V, Toledano D, et al. . Idiopathic inflammatory myopathies: CT characteristics of interstitial lung disease and their association(s) with myositis-specific autoantibodies. Eur Radiol. (2022). 10.1007/s00330-021-08411-w. [Epub ahead of print]. PubMed DOI

Linos E, Fiorentino D, Lingala B, Krishnan E, Chung L. Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey. Arthritis Res Ther. (2013) 15:R7. 10.1186/ar4135 PubMed DOI PMC

Triantafyllias K, Cavagna L, Klonowski A, Drott U, Fiehn C, Wendel S, et al. . Possible misclassification of cardiovascular risk by SCORE in antisynthetase syndrome: results of the pilot multicenter study RI.CAR.D.A. Rheumatology. (2021) 60:1300–12. 10.1093/rheumatology/keaa525 PubMed DOI

Urowitz MB, Ibanez D, Su J, Gladman DD. Modified Framingham risk factor score for systemic lupus erythematosus. J Rheumatol. (2016) 43:875–9. 10.3899/jrheum.150983 PubMed DOI

D'Agostino RB, Sr., Vasan RS, Pencina MJ, Wolf PA, Cobain M, et al. . General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. (2008) 117:743–53. 10.1161/CIRCULATIONAHA.107.699579 PubMed DOI

Cheng IT, Wong KT, Li EK, Wong PCH, Lai BT, Yim IC, et al. . Comparison of carotid artery ultrasound and Framingham risk score for discriminating coronary artery disease in patients with psoriatic arthritis. RMD Open. (2020) 6:e001364. 10.1136/rmdopen-2020-001364 PubMed DOI PMC

Soltesz P, Der H, Kerekes G, Szodoray P, Szucs G, Danko K, et al. . A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima-media in patients with systemic autoimmune diseases. Clin Rheumatol. (2009) 28:655–62. 10.1007/s10067-009-1118-y PubMed DOI

Vincze M, Der H, Kerekes G, Szodoray P, Zeher M, Danko K, et al. . Decreased flow-mediated dilatation with increased arterial stiffness and thickness as early signs of atherosclerosis in polymyositis and dermatomyositis patients. Clin Rheumatol. (2014) 33:1635–41. 10.1007/s10067-014-2561-y PubMed DOI

Eimer MJ, Brickman WJ, Seshadri R, Ramsey-Goldman R, McPherson DD, Smulevitz B, et al. . Clinical status and cardiovascular risk profile of adults with a history of juvenile dermatomyositis. J Pediatr. (2011) 159:795–801. 10.1016/j.jpeds.2011.05.015 PubMed DOI PMC

Diederichsen LP, Diederichsen AC, Simonsen JA, Junker P, Sondergaard K, Lundberg IE, et al. . Traditional cardiovascular risk factors and coronary artery calcification in adults with polymyositis and dermatomyositis: a Danish multicenter study. Arthritis Care Res. (2015) 67:848–54. 10.1002/acr.22520 PubMed DOI

Wang H, Tang J, Chen X, Li F, Luo J. Lipid profiles in untreated patients with dermatomyositis. J Eur Acad Dermatol Venereol. (2013) 27:175–9. 10.1111/j.1468-3083.2011.04437.x PubMed DOI

Limaye VS, Lester S, Blumbergs P, Roberts-Thomson PJ. Idiopathic inflammatory myositis is associated with a high incidence of hypertension and diabetes mellitus. Int J Rheum Dis. (2010) 13:132–7. 10.1111/j.1756-185X.2010.01470.x PubMed DOI

de Moraes MT, de Souza FH, de Barros TB, Shinjo SK. Analysis of metabolic syndrome in adult dermatomyositis with a focus on cardiovascular disease. Arthritis Care Res. (2013) 65:793–9. 10.1002/acr.21879 PubMed DOI

Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med. (2008) 121:S21–31. 10.1016/j.amjmed.2008.06.014 PubMed DOI

Miossi R, Souza FHCd, Shinjo SK. Could C-reactive protein and erythrocyte sedimentation rate support monitoring of dermatomyositis and polymyositis activity? Medical Express. (2017) 4:1–6. 10.5935/MedicalExpress.2017.02.05 PubMed DOI

Hanisch F, Zierz S. C-Reactive protein in idiopathic inflammatory myopathies. Myopain. (2015) 23:45–51. 10.3109/10582452.2013.852151 DOI

Marie I, Hachulla E, Cherin P, Dominique S, Hatron PY, Hellot MF, et al. . Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. (2002) 47:614–22. 10.1002/art.10794 PubMed DOI

Witt LJ, Curran JJ, Strek ME. The diagnosis and treatment of antisynthetase syndrome. Clin Pulm Med. (2016) 23:218–26. 10.1097/CPM.0000000000000171 PubMed DOI PMC

Katzap E, Barilla-LaBarca ML, Marder G. Antisynthetase syndrome. Curr Rheumatol Rep. (2011) 13:175–81. 10.1007/s11926-011-0176-8 PubMed DOI

Howard OM, Dong HF, Yang D, Raben N, Nagaraju K, Rosen A, et al. . Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med. (2002) 196:781–91. 10.1084/jem.20020186 PubMed DOI PMC

Taher R, Sara JD, Toya T, Shepherd R, Moder K, Lerman LO, et al. . Secondary Raynaud's phenomenon is associated with microvascular peripheral endothelial dysfunction. Microvasc Res. (2020) 132:104040. 10.1016/j.mvr.2020.104040 PubMed DOI

Braunersreuther V, Mach F, Steffens S. The specific role of chemokines in atherosclerosis. Thromb Haemost. (2007) 97:714–21. 10.1160/TH07-01-0036 PubMed DOI

de Jager SC, Bot I, Kraaijeveld AO, Korporaal SJ, Bot M, van Santbrink PJ, et al. . Leukocyte-specific CCL3 deficiency inhibits atherosclerotic lesion development by affecting neutrophil accumulation. Arterioscler Thromb Vasc Biol. (2013) 33:e75–83. 10.1161/ATVBAHA.112.300857 PubMed DOI

de Jager SC, Kraaijeveld AO, Grauss RW, de Jager W, Liem SS, van der Hoeven BL, et al. . CCL3 (MIP-1 alpha) levels are elevated during acute coronary syndromes and show strong prognostic power for future ischemic events. J Mol Cell Cardiol. (2008) 45:446–52. 10.1016/j.yjmcc.2008.06.003 PubMed DOI

de Jager SC, Bongaerts BW, Weber M, Kraaijeveld AO, Rousch M, Dimmeler S, et al. . Chemokines CCL3/MIP1alpha, CCL5/RANTES and CCL18/PARC are independent risk predictors of short-term mortality in patients with acute coronary syndromes. PLoS ONE. (2012) 7:e45804. 10.1371/journal.pone.0045804 PubMed DOI PMC

Tatara Y, Ohishi M, Yamamoto K, Shiota A, Hayashi N, Iwamoto Y, et al. . Macrophage inflammatory protein-1beta induced cell adhesion with increased intracellular reactive oxygen species. J Mol Cell Cardiol. (2009) 47:104–11. 10.1016/j.yjmcc.2009.03.012 PubMed DOI

Xu F, Lv S, Chen Y, Song X, Jin Z, Yuan F, et al. . Macrophage inflammatory protein-1beta and fibrinogen are synergistic predictive markers of prognosis of intermediate coronary artery lesions. Cardiology. (2012) 121:12–9. 10.1159/000335886 PubMed DOI

Niu J, Kolattukudy PE. Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications. Clin Sci. (2009) 117:95–109. 10.1042/CS20080581 PubMed DOI

Herder C, Baumert J, Thorand B, Martin S, Lowel H, Kolb H, et al. . Chemokines and incident coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol. (2006) 26:2147–52. 10.1161/01.ATV.0000235691.84430.86 PubMed DOI

Altara R, Manca M, Hessel MH, Gu Y, van Vark LC, Akkerhuis KM, et al. . CXCL10 is a circulating inflammatory marker in patients with advanced heart failure: a pilot study. J Cardiovasc Transl Res. (2016) 9:302–14. 10.1007/s12265-016-9703-3 PubMed DOI

Li Q, Ming T, Wang Y, Ding S, Hu C, Zhang C, et al. . Increased Th9 cells and IL-9 levels accelerate disease progression in experimental atherosclerosis. Am J Transl Res. (2017) 9:1335–43. PubMed PMC

Gregersen I, Skjelland M, Holm S, Holven KB, Krogh-Sorensen K, Russell D, et al. . Increased systemic and local interleukin 9 levels in patients with carotid and coronary atherosclerosis. PLoS ONE. (2013) 8:e72769. 10.1371/journal.pone.0072769 PubMed DOI PMC

Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, Metsios GS, Nightingale P, Kita MD, et al. . Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology. (2008) 47:72–5. 10.1093/rheumatology/kem311 PubMed DOI

Ruyssen-Witrand A, Fautrel B, Saraux A, Le Loet X, Pham T. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine. (2011) 78:23–30. 10.1016/j.jbspin.2010.02.040 PubMed DOI

Wright K, Crowson CS, Gabriel SE. Cardiovascular comorbidity in rheumatic diseases: a focus on heart failure. Heart Fail Clin. (2014) 10:339–52. 10.1016/j.hfc.2013.10.003 PubMed DOI PMC

Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, et al. . Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. (2019) 380:752–62. 10.1056/NEJMoa1809798 PubMed DOI PMC

Tisseverasinghe A, Bernatsky S, Pineau CA. Arterial events in persons with dermatomyositis and polymyositis. J Rheumatol. (2009) 36:1943–6. 10.3899/jrheum.090061 PubMed DOI

Vencovsky J, Alexanderson H, Lundberg IE. Idiopathic inflammatory myopathies. Rheum Dis Clin North Am. (2019) 45:569–81. 10.1016/j.rdc.2019.07.006 PubMed DOI

Willeit P, Tschiderer L, Allara E, Reuber K, Seekircher L, Gao L, et al. . Carotid intima-media thickness progression as surrogate marker for cardiovascular risk: meta-analysis of 119 clinical trials involving 100 667 patients. Circulation. (2020) 142:621–42. 10.1161/CIRCULATIONAHA.120.046361 PubMed DOI PMC

Cardiovascular risk in myositis patients compared with the general population